ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0779
0.00%
Brent Oil
72.72
0.00%
Bitcoin
98,381.14
0.64%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) Noticias

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LTRN
FechaHoraFuenteTítuloSímboloCompañía
09/12/202407:15Business WireLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
03/12/202407:00Business WireLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)NASDAQ:LTRNLantern Pharma Inc
26/11/202407:45Business WireLantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic LethalityNASDAQ:LTRNLantern Pharma Inc
19/11/202407:00Business WireLantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
07/11/202415:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
07/11/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
07/11/202415:05Business WireLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
05/11/202407:00Business WireStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNASDAQ:LTRNLantern Pharma Inc
31/10/202407:00Business WireLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
23/10/202407:45Business WireLantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024NASDAQ:LTRNLantern Pharma Inc
21/10/202407:00Business WireLantern Pharma to Host & Participate in Two Public Webinars During OctoberNASDAQ:LTRNLantern Pharma Inc
15/10/202408:07Business WireLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDANASDAQ:LTRNLantern Pharma Inc
23/09/202407:00Business WireLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersNASDAQ:LTRNLantern Pharma Inc
08/08/202415:01Business WireLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
07/08/202408:31Business Wire Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024NASDAQ:LTRNLantern Pharma Inc
05/08/202407:00Business WireLantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient CohortNASDAQ:LTRNLantern Pharma Inc
01/08/202407:00Business WireLantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
17/07/202415:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
10/07/202407:30Business WireLantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184NASDAQ:LTRNLantern Pharma Inc
12/06/202406:30Business WireLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284NASDAQ:LTRNLantern Pharma Inc
10/06/202423:16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LTRNLantern Pharma Inc
24/05/202415:08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LTRNLantern Pharma Inc
24/05/202415:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LTRNLantern Pharma Inc
13/05/202400:30Business WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
09/05/202415:02Business WireLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
06/05/202402:00Business WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismNASDAQ:LTRNLantern Pharma Inc
02/05/202406:30Business WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
24/04/202407:00Business WireLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentNASDAQ:LTRNLantern Pharma Inc
22/04/202407:12Business WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanNASDAQ:LTRNLantern Pharma Inc
18/03/202415:02Business WireLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Su Consulta Reciente

COIN
DOGEUSD
Dogecoin
NASDAQ
TSLA
Tesla
COIN
ETHUSD
Ethereum
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
FX
USDMXN
US Dollar vs MXN
AMEX
XLF
Financial Select Sector
NYSE
NKE
Nike
NYSE
VZ
Verizon Communications
NYSE
CVX
Chevron
AMEX
XLE
Energy Select Sector SPDR
NYSE
KO
Coca Cola
COIN
XRPUSD
Ripple
NASDAQ
GOOGL
Alphabet
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados